Discover Tenders by Drugs Cancer Oncology Sector

Find the most relevant tenders for Drugs Cancer Oncology. Access the latest tender notices from various government and private organizations published across hundreds of websites and newspapers.Obtain complete and accurate information on Drugs Cancer Oncology tenders, including all tender documents, RFPs, RFQs,and more. Utilize our advanced filters to search for Drugs Cancer Oncology tenders by organization, tender value, opening and closing dates, and more.

Filter Your Search

Country

Sector

Region

Funding Agency

Conclusion Not Excluding Drug Discount Agreement According To Section 130A Paragraph 8 Sgb V Through An Open House Model For The Active Ingredient Fampridine Atc Code According To Who N07Xx07

Deadline: 28 Feb 2026

Germany

Ref. No.: 5037763

EMD:Ref Document

Bid Value: Ref Document

94 Days Left

Open Framework Agreement On Drug Discounts In Accordance With Section 130A Paragraph 8 Sgb V With The Possibility Of Joining At Any Time So Called Approval Model 2024 04

Deadline: 05 Apr 2026

Germany

Ref. No.: 4943211

EMD:Ref Document

Bid Value: Ref Document

130 Days Left

Conclusion Of A Non Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Medicines With The Active Ingredient Alitretinoin Atc Code D11Ah04

Deadline: 27 Mar 2026

Germany

Ref. No.: 4900610

EMD:Ref Document

Bid Value: Ref Document

121 Days Left

Conclusion Of A Non Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Medicines With The Active Ingredient Leuprorelin Atc Code L02Ae02

Deadline: 27 Mar 2026

Germany

Ref. No.: 4899956

EMD:Ref Document

Bid Value: Ref Document

121 Days Left

Conclusion Of A Non Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Medicines With The Active Ingredient Flupentixol Atc Code N05Af01

Deadline: 27 Mar 2026

Germany

Ref. No.: 4899215

EMD:Ref Document

Bid Value: Ref Document

121 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Eptinezumab N02Cd05 As Part Of A So Called Open House Model

Deadline: 28 Feb 2026

Germany

Ref. No.: 4646012

EMD:Ref Document

Bid Value: Ref Document

94 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Pancreatin Lipase Containing Multienzymes A09Aa02 As Part Of A So Called Open House Model

Deadline: 28 Feb 2026

Germany

Ref. No.: 4644671

EMD:Ref Document

Bid Value: Ref Document

94 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Fentanyl Only Sublingual Tablets Nasal Dosage Spray Or Lozenges N02Ab03 As Part Of A So C

Deadline: 28 Feb 2026

Germany

Ref. No.: 4643255

EMD:Ref Document

Bid Value: Ref Document

94 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Drugs With The Active Ingredients Fluticasone And Azelastine R01Ad28 As Part Of A So Called Open House Model

Deadline: 28 Feb 2026

Germany

Ref. No.: 4642060

EMD:Ref Document

Bid Value: Ref Document

94 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Tolvaptan C03Xa01 As Part Of A So Called Open House Model

Deadline: 28 Feb 2026

Germany

Ref. No.: 4641684

EMD:Ref Document

Bid Value: Ref Document

94 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Pimecrolimus D11Ah02 As Part Of A So Called Open House Model

Deadline: 28 Feb 2026

Germany

Ref. No.: 4640967

EMD:Ref Document

Bid Value: Ref Document

94 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Tolvaptan G04Bx21 As Part Of A So Called Open House Model

Deadline: 28 Feb 2026

Germany

Ref. No.: 4640900

EMD:Ref Document

Bid Value: Ref Document

94 Days Left

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingredient Fingolimod L04Ae01 As Part Of A So Called Open House Model

Deadline: 28 Feb 2026

Germany

Ref. No.: 4640403

EMD:Ref Document

Bid Value: Ref Document

94 Days Left

Conclusion Of A Non Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Trientine Atc A16Ax12 For The Period May 1 2024 April 30 2026

Deadline: 05 Mar 2026

Germany

Ref. No.: 4539705

EMD:Ref Document

Bid Value: Ref Document

99 Days Left

Conclusion Of A Non Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredients Sofosbuvir And Velpatasvir Atc J05Ap55 For The Period May 1 2024 April 30 2026

Deadline: 05 Mar 2026

Germany

Ref. No.: 4539071

EMD:Ref Document

Bid Value: Ref Document

99 Days Left

Showing 38176 to 38190 of 38252 results

‹
1
2
...
2542
2543
2544
2545
2546
2547
2548
2549
2550
2551
›

Discover Tenders by Drugs Cancer Oncology Sector

Filter Your Search

Tenders by Countries

Browse Popular Sectors

Projects by Regions

Funding Agency

Support

CONTACT DETAILS

Discover Tenders by Drugs Cancer Oncology Sector

Filter Your Search

FREE Trial plan for all new users!